title: Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer.
abstract: MicroRNA-195 (miR-195) is a tumor suppressor that plays an important role in tumorigenesis. There are few studies on miR-195 expression in breast cancer patients and the results have been inconsistent; therefore, this study examined miR-195 expression in the serum of BC patients. Samples from 102 normal subjects and 210 subjects with BC who had detailed clinical follow-up information available were selected. An internal reference (miR-16) and serum miR-195 were amplified and quantitatively detected by SYBR green-based real-time RT-PCR. We analyzed the differences in miR-195 levels between BC and healthy cases and the relationships between the miR-195 level and TNM stage and other clinicopathological parameters. In addition, changes in miR-195 levels were examined for 21 BC cases using paired samples before and after neoadjuvant chemotherapy. miR-195 was downregulated in BC compared with control samples (P = 0.000, Mann-Whitney U test). The sensitivity and specificity of miR-195 in the diagnosis of BC were 69.0 and 89.2 %, respectively; whereas, the sensitivities of carcinoembryonic antigen (CEA) and carbohydrate antigen 153 (CA153) were only 15.08 and 21.1 %, respectively. Remarkably, serum miR-195 had higher sensitivity, 73.97 % (108/146), as a tumor marker in the diagnosis of early stage BC [ductal carcinoma in situ, tumor-node-metastasis (TNM) I, II] compared with the conventional tumor markers CA153 and CEA (12.41 and 7.59 %). Moreover, compared with CEA and CA153, miR-195 had a higher sensitivity for detecting the response to neoadjuvant chemotherapy and significantly increased, more than twofold, after neoadjuvant chemotherapy (P = 0.025, paired t test) in 52.381 % (11/21) of BC cases. However, there were no significant relationships between miR-195 expression and other clinicopathological parameters (TNM stage/pathotype/ER/PR/lymph node status). Our data indicate serum miR-195 is a promising tumor marker for BC diagnosis and general screening, especially for early stage BC. The high sensitivity of miR-195 to neoadjuvant chemotherapy may lay the foundation for future studies on the use of miRNA-based methods for monitoring BC treatment and therapy.
authors.affiliation: Department of Orthopedics, The LuHe Teaching Hospital of Capital Medical University, Beijing, 101149, China.
authors.forename: Fu-long
authors.initials: FL
authors.lastname: Zhao
authors.forename: Yue-chao
authors.initials: YC
authors.lastname: Dou
authors.forename: Xue-fei
authors.initials: XF
authors.lastname: Wang
authors.forename: Da-cheng
authors.initials: DC
authors.lastname: Han
authors.forename: Zhen-gang
authors.initials: ZG
authors.lastname: Lv
authors.forename: Shuang-lei
authors.initials: SL
authors.lastname: Ge
authors.forename: Ya-kui
authors.initials: YK
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000235:genetics* / Q000628:therapy; D002272:Carcinoembryonic Antigen / Q000097:blood; D016022:Case-Control Studies; D015536:Down-Regulation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005819:Genetic Markers; D006801:Humans; D008207:Lymphatic Metastasis; D035683:MicroRNAs / Q000097:blood* / Q000235:genetics*; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D002272:Carcinoembryonic Antigen; D005819:Genetic Markers; C552722:MIRN195 microRNA, human; D035683:MicroRNAs
references.citation: Genome Biol. 2004;5(3):R13
references.pmid: 15003116
references.citation: Clin Chem. 2008 Mar;54(3):482-90
references.pmid: 18218722
references.citation: Ann Oncol. 2008 Apr;19(4):675-81
references.pmid: 18037623
references.citation: PLoS One. 2009;4(5):e5532
references.pmid: 19440243
references.citation: Oncogene. 2011 Mar 3;30(9):1082-97
references.pmid: 21057537
references.citation: Hepatology. 2009 Jul;50(1):113-21
references.pmid: 19441017
references.citation: JAMA. 2005 Mar 9;293(10):1245-56
references.pmid: 15755947
references.citation: Nat Rev Genet. 2004 Jul;5(7):522-31
references.pmid: 15211354
references.citation: Oncologist. 2010;15(7):673-82
references.pmid: 20576643
references.citation: Cancer Res. 2007 Jul 1;67(13):6092-9
references.pmid: 17616664
references.citation: Gut. 2009 Oct;58(10):1375-81
references.pmid: 19201770
references.citation: Med Oncol. 2012 Jun;29(2):919-27
references.pmid: 21390519
references.citation: Biochem Biophys Res Commun. 2010 Sep 17;400(2):236-40
references.pmid: 20727858
references.citation: Clin Cancer Res. 2011 Apr 1;17(7):1722-30
references.pmid: 21350001
references.citation: Clin Cancer Res. 2008 May 1;14(9):2588-92
references.pmid: 18451220
references.citation: J Cell Physiol. 2011 Oct;226(10):2535-42
references.pmid: 21792910
references.citation: Mol Cancer. 2006 Sep 18;5:37
references.pmid: 16982006
references.citation: Int J Cancer. 2009 Jul 15;125(2):345-52
references.pmid: 19378336
references.citation: Breast Cancer Res. 2011 Mar 04;13(2):R24
references.pmid: 21375733
references.citation: PLoS One. 2008 Sep 05;3(9):e3148
references.pmid: 18773077
references.citation: J Gastroenterol Hepatol. 2009 Apr;24(4):652-7
references.pmid: 19175831
references.citation: Int J Cancer. 2010 Jul 1;127(1):118-26
references.pmid: 19876917
references.citation: Gynecol Oncol. 2009 Jan;112(1):55-9
references.pmid: 18954897
references.citation: Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004
references.pmid: 14973191
references.citation: Cancer Treat Rev. 2000 Apr;26(2):91-102
references.pmid: 10772967
references.citation: Development. 2005 Nov;132(21):4645-52
references.pmid: 16224044
references.citation: Cancer Prev Res (Phila). 2009 Sep;2(9):807-13
references.pmid: 19723895
references.citation: Cell. 2001 Dec 28;107(7):823-6
references.pmid: 11779458
references.citation: Cancer Res. 2007 Dec 1;67(23):11111-6
references.pmid: 18056433
references.citation: Science. 2004 Apr 23;304(5670):594-6
references.pmid: 15105502
references.citation: Cancer Res. 2007 Sep 15;67(18):8699-707
references.pmid: 17875710
references.citation: Nat Rev Cancer. 2006 Apr;6(4):259-69
references.pmid: 16557279
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Curr Opin Genet Dev. 2005 Oct;15(5):563-8
references.pmid: 16099643
references.citation: PLoS One. 2010 Oct 29;5(10):e13735
references.pmid: 21060830
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4402-7
references.pmid: 19246379
references.citation: Clin Cancer Res. 2009 Dec 15;15(24):7684-7692
references.pmid: 19996210
references.citation: Mod Pathol. 2009 Feb;22(2):197-205
references.pmid: 18677302
references.citation: Gastroenterology. 2007 Aug;133(2):647-58
references.pmid: 17681183
references.citation: CA Cancer J Clin. 2011 Nov-Dec;61(6):409-18
references.pmid: 21969133
references.citation: Nucleic Acids Res. 2008 Sep;36(16):5391-404
references.pmid: 18701644
references.citation: Nature. 2004 Sep 16;431(7006):350-5
references.pmid: 15372042
references.citation: Cell Res. 2008 Oct;18(10):997-1006
references.pmid: 18766170
references.citation: Lancet. 2003 Apr 26;361(9367):1405-10
references.pmid: 12727392
references.citation: Annu Rev Cell Dev Biol. 2007;23:175-205
references.pmid: 17506695
references.citation: Br J Cancer. 2010 Mar 2;102(5):883-91
references.pmid: 20160723
references.citation: PLoS One. 2011 Mar 28;6(3):e18286
references.pmid: 21464941
references.citation: Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
references.pmid: 18663219
references.citation: Cell. 2004 Jan 23;116(2):281-97
references.pmid: 14744438
references.citation: Gastroenterology. 2006 Jun;130(7):2113-29
references.pmid: 16762633